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Platelet apheresis sometimes causes persistent aggregates (PA). This study
(n = 211) shows that changing the apheresis settings to reach fixed product vol-
umes instead of yields does not influence PA incidence, even though PA products
on average contain more platelets than controls. Furthermore, logistic regression
was used to model if PA can be predicted on the basis of certain predonation
parameters. PA donation history was the only parameter retained, proving a
strong determinant of predictability [AUC = 0.735 (SE = 0.022)]. Consequently,
donations from a donor with previous PA history are 7.8 times more likely to
contain PA than from a donor without preceding history.
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Introduction
Apheresis procedures may cause platelet aggregation.
These generally dissipate, but some persist throughout the
entire storage period [1]. Products with persisting aggre-
gates (PA) may be quarantined, destroyed or distributed
in which case an evaluation procedure can be used as a
guideline [2]. Concentrates with PA contain more platelets
than aggregate-free (AF) ones [3]. Moreover, mildly
increased storage lesion was observed in PA products ver-
sus AF controls [3, 4]. Our previous study included 180
donations with PA and an equal number of AF controls.
These were collected using an apheresis protocol that pro-
jected a fixed platelet yield. However, the introduction of
pathogen inactivation (Intercept, Cerus Corporation, Con-
cord, CA) at our blood institute prompted revision of that
particular protocol to comply with the inclusion criteria.
Now, defined volume ranges are projected, resulting in
(more) variable platelet yields instead. This raised the fol-
lowing questions: Does the new collection protocol influ-
ence the incidence of PA? Does it affect the previously
observed differences between PA and AF products? We
furthermore questioned whether the occurrence of PA can
be predicted based on an algorithm containing only pre-
donation parameters.
Single-donor platelet concentrates were collected by
Trima Accel (Terumo BCT) with an inlet to anticoagulant
(ACD-A) ratio of 11:1 at an infusion rate of 1.0 ml/min/l of
estimated total blood volume. Additive solution was auto-
matically supplemented following donation. Final product
volumes between 300 and 420 ml were projected following
the Intercept inclusion criteria. In case a larger collection
was possible, volumes above 610 mL (double collection)
were projected to allow splitting to the compliant volume
range. All products were scored for PA presence by trained
staff according to internal guidelines [2]. The AF group cri-
teria were as described [3]. To define whether donors had
donated PA prior to inclusion in this study, historical
records of PA incidence were reviewed. These range from
the start of systematically recording the problem (June
2012) until the end of this study period. Statistical analysis
was with SAS (v9.3, SAS Institute Inc, Cary, NC)).
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The new collection protocol was installed by July 2014,
and data collection was between November 2014 and April
2015. In that period, 211 donations with PA were registered
on a total of 5664 successful procedures yielding a 3.7%
incidence rate, which is not significantly different from the
previous rate [3]. Concurrently, 204 AF controls were col-
lected. On average, PA donations were from donors having
higher circulating platelet counts (274 – 55x103/ll vs.
261 – 49x103/ll, Fig. 1a), delivering products with a
higher platelet concentration (1094 – 219x103/ll vs.
1041 – 205x103/ll, Fig. 1b). The frequency of single and
double donations was tabulated, and a significantly higher
number of double donations were found in the PA group
(Fig. 1c) confirmed by overall more high-yield products
(Fig. 1d) in that arm. This indicates that independent of the
collection protocol, PA incidence is higher in donors with
high circulating platelet counts. Yet, the absolute difference
in mean platelet concentration remains small and distribu-
tions overlap, suggesting that this parameter is not suffi-
cient to predict the incidence of PA prior to donation.
Consequently, we used additional predonation data to
build a logistic regression model to predict PA donation.
Mean platelet volume, gender, whole-blood platelet con-
centration, haematocrit, PA donation history, apheresis
product platelet concentration and volume were included
as variables in a backward-selection logistic regression.
Only PA donation history (P < 0.0001) was retained in the
final model, proving a strong determinant of predictability
[AUC = 0.735 (SE = 0.022)]. Based on the odds ratio, a
donation from a donor with PA history is thus 7.8 times
more likely to contain PA than from a donor without pre-
ceding history. The other parameters were not substan-
tially improving the model. Of note, all 204 donors with a
PA donation history (154/211 in the PA, 50/204 in the AF
arm) had significantly (P < 0.0001) higher whole-blood
platelet concentrations (278 – 54x103/ll) than those with-
out (257 – 48x103/ll).
For blood institutions worldwide, products with PA pose
a problem. Medical staff performing transfusion are
required to visually inspect prior to administration in order
to prevent transfusion of aberrantly appearing products. If
transfusion of PA is tolerated, operators may become
accustomed to aberrantly looking products, thus jeopardiz-
ing good practice. Moreover, it is not entirely clear whether
PA containing platelet concentrates are safe for transfusion
or whether the quality is sufficiently high. These products
therefore often go to waste. At 4% incidence, this wastage
is a significant economic cost for (blood) communities. The
current update from our longitudinal survey now shows
that PA history is a strong determinant of future donations
with PA. Our data suggest that this may be caused by the
inherent difference in whole-blood platelet concentration
between donors. A practical consequence of the higher pla-
telet concentration in PA donor’s whole blood is the larger
products these donors provide, but it is unclear whether
collection of smaller products from such donors would help
driving back PA incidence. To mitigate PA incidence, pre-
vious reports have suggested to increase the anticoagulant
to inlet ratio, but additional research is required to confirm
utility and investigate the consequences for donor and
Fig. 1 Donor and donation variables in
donations with PA compared to AF controls. (a)
Whole-blood platelet concentration of the
donor and (b) platelet concentration in the
ﬁnal product, following the addition of
additive solution. Boxes represent median with
interquartile ranges, (+) indicates data mean,
and whiskers indicate the 10–90 percentile. (c)
The absolute frequency of double-apheresis
platelet concentrates (≥600 ml) is shown by
the hatched bars, while single donations by
open bars. (d) The product platelet yield is
shown by plotting all individual data with the
median (line) and interquartile ranges
(whiskers) embedded.
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operators [1, 5]. With the adoption of Intercept pathogen
inactivation, PA have disappeared in our blood institution.
This can be attributed to the additional filtration in the
Intercept pathogen inactivation process which is intended
to remove putative compound adsorption device beads but
coincidently retains platelet aggregates. Therefore, the
mere visual aspect of PA in Intercept-treated products is no
longer preventing product issuance. However, removal of
aggregates does not necessarily guarantee that the (small)
increase in storage lesion observed in products with PA
[3, 4] will normalize.
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